Tel.: +33-4-72-73-80-23, Fax: +33-4-72-73-83-42
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Early Detection and Diagnosis
You have full text access to this OnlineOpen article
Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study†
Article first published online: 1 APR 2011
DOI: 10.1002/ijc.25986
Copyright © 2011 UICC
Additional Information
How to Cite
Johansson, M., Holmström, B., Hinchliffe, S. R., Bergh, A., Stenman, U.-H., Hallmans, G., Wiklund, F. and Stattin, P. (2012), Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study. Int. J. Cancer, 130: 129–137. doi: 10.1002/ijc.25986
- †
Conflicts of interest: Ulf-Håkan Stenman holds a patent for free PSA, consulting for Wallac, lectures ISOBM meeting sponsored by Abbot Diagnostics.
- §
Tel.: +33-4-72-73-80-23, Fax: +33-4-72-73-83-42
Publication History
- Issue published online: 27 OCT 2011
- Article first published online: 1 APR 2011
- Accepted manuscript online: 15 FEB 2011 02:33PM EST
- Manuscript Accepted: 30 DEC 2010
- Manuscript Received: 19 OCT 2010
Funded by
- Centre for Research and Development, Uppsala University, County Council of Gävleborg, Sweden
- Lion's Cancer Research Foundation at Umeå University, Sweden
- Percy Falk Foundation, Sweden
- Västerbotten County Council, Sweden
- Swedish Cancer Society, Sweden
- Swedish Scientific Council, Sweden
- Regional Government of Västerbotten, Sweden
Keywords:
- early detection;
- prostate cancer;
- prostate-specific antigen;
- single-nucleotide polymorphism
Abstract
The aim of this study was to investigate if a genetic risk score including 33 common genetic variants improves prediction of prostate cancer when added to measures of prostate-specific antigen (PSA). We conducted a case–control study nested within the Northern Sweden Health and Disease Cohort (NSHDC), a prospective cohort in northern Sweden. A total of 520 cases and 988 controls matched for age, and date of blood draw were identified by linkage between the regional cancer register and the NSHDC. Receiver operating characteristic curves with area under curve (AUC) estimates were used as measures of prostate cancer prediction. The AUC for the genetic risk score was 64.3% [95% confidence interval (CI) = 61.4–67.2], and the AUC for total PSA and the ratio of free to total PSA was 86.2% (95% CI = 84.4–88.1). A model including the genetic risk score, total PSA and the ratio of free to total PSA increased the AUC to 87.2% (95% CI = 85.4–89.0, p difference = 0.002). The addition of a genetic risk score to PSA resulted in a marginal improvement in prostate cancer prediction that would not seem useful for clinical risk assessment.